RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID

Summary

The Mutanome Engineered RNA Immuno-Therapy (MERIT) study introduced a novel concept for Individualized Cancer Immunotherapy (IVAC®) to treat each patient with the relevant and immunogenic RNA vaccines for a given patient's tumor. The TNBC-MERIT trial used two complementary strategies, the WAREHOUSE and the IVAC® MUTANOME concept, resulting in two custom-made IVAC® investigational medicinal products (IMPs) (IVAC\_W\_bre1\_uID and IVAC\_M\_uID) for each individual patient.

Timeline

Start

2016-10

Primary completion

2020-05-13

Completion

2023-05-17

Publications

• Sahin U, Schmidt M, Derhovanessian E, Cortini A, Vogler I, Omokoko T, Godehardt E, Attig S, Newrzela S, Grutzner J, Bidmon N, Bolte S, Brachtendorf S, Stuhlmann T, Langer D, Brune D, Blake J, Feldner A, Lindman H, Schneeweiss A, Eichbaum M, Tureci O. Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC. Nature. 2026 Mar;651(8107):1088-1096. doi: 10.1038/s41586-025-10004-2. Epub 2026 Feb 18.

Drugs

Indications